PB2554: DESIGN OF A PHASE 1B OPEN-LABEL STUDY TO ASSESS THE SAFETY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF POVETACICEPT (ALPN-303) IN SUBJECTS WITH AUTOIMMUNE CYTOPENIAS (RUBY-4)
Catherine M Broome,
Donald Arnold,
Caroline Piatek,
Eun-Ju Lee,
Hany Zayed,
Stanford Peng,
Ismail Simsek
Affiliations
Catherine M Broome
1 MedStar Georgetown University Hospital, Washington, United States
Donald Arnold
2 McMaster University, Department of Medicine, Hamilton, Canada
Caroline Piatek
3 University of Southern California, Jane Anne Nohl Division of Hematology, Los Angeles, United States
Eun-Ju Lee
4 New York Presbyterian Hospital - Weill Cornell Medicine, Division of Hematology and Medical Oncology, New York, United States
Hany Zayed
5 Alpine Immune Sciences, Inc., Seattle, United States
Stanford Peng
5 Alpine Immune Sciences, Inc., Seattle, United States
Ismail Simsek
5 Alpine Immune Sciences, Inc., Seattle, United States
